Log In
Print
BCIQ
Print
Print this Print this
 

Kogenate Bayer, Kogenate FS (BAY14-2222)

Also known as: Kogenate, antihemophilic factor

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionRecombinant Factor VIII (rFVIII) formulated with sucrose
Molecular Target Factor VIII
Mechanism of ActionProcoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsPrevent bleeding episodes and the risk of joint damage in patients with hemophilia A; Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A; Secondary prophylaxis of bleeding episodes and joint damage in patients with hemophilia A; Treat and prevent bleeding in patients with hemophilia A; Treat hemophilia A
Regulatory Designation

U.S. - Undisclosed Review (Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today